Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells

Lapatinib is an inhibitor of human epidermal growth factor receptor 2 (HER2), which is overexpressed in 20-25% of breast cancers. Clinically, lapatinib has shown promising benefits for HER2-positive breast cancer patients; however, patients eventually acquire resistance, limiting its long-term use....

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncotarget
Hoofdauteurs: Huang, Wei-Chien, Hung, Chao-Ming, Wei, Ching-Ting, Chen, Tsung-Ming, Chien, Pei-Hsuan, Pan, Hsiao-Lin, Lin, Yueh-Ming, Chen, Yun-Ju
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Impact Journals LLC 2016
Onderwerpen:
Research Paper
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5308732/
https://ncbi.nlm.nih.gov/pubmed/27694691
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11471
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items